All lobbying filings

GILEAD SCIENCES, INC.

GILEAD SCIENCES, INC. filed a Q2 report for GILEAD SCIENCES INC on July 21, 2025.

Lobbying for GILEAD SCIENCES INC

All filings by GILEAD SCIENCES, INC. · Everything GILEAD SCIENCES INC has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 21, 2025

Expenses

$1,700,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Lobbyists on this filing 1

RILEY SWINEHART New on this filing

Previously held: Staff Assistant, The White House (6/2004-8/2006) Confidential Assistant, Dept of HHS (8/2006-1/2009) Professional Staff Member, Senate HELP Committee (6/2011-2/2013) Minority Staff Director (2/2013-5/2014)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 14

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Health Issues

Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.

Trade (domestic/foreign)

Advocate on drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries.

Medicare/Medicaid

Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.

Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding.

Budget/Appropriations

Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.

Taxation/Internal Revenue Code

Legislative and regulatory proposals to change international and domestic corporate tax law and policy.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.